Vithalkar Megh Pravin, Sandra K S, Bharath H B, Krishnaprasad B, Fayaz S M, Sathyanarayana B, Nayak Yogendra
Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka 576104, India.
Department of Biotechnology, Manipal Institute of Technology, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India.
Int Immunopharmacol. 2025 Feb 6;147:113979. doi: 10.1016/j.intimp.2024.113979. Epub 2025 Jan 1.
This review explores the progressive domain of network pharmacology and its potential to revolutionize therapeutic approaches for Interstitial Lung Diseases (ILDs), a collective term encompassing Interstitial Pneumonia, Pneumoconiosis, Connective Tissue Disease-related ILDs, and Sarcoidosis. The exploration focuses on the profound legacy of traditional medicines, particularly Ayurveda and Traditional Chinese Medicines (TCM), and their largely unexplored capacity in ILD treatment. These ancient healing systems, characterized by their holistic methodologies and multifaceted treatment modalities, offer a promising foundation for discovering innovative therapeutic strategies. Moreover, the review underscores the amalgamation of artificial intelligence (AI) and machine learning (ML) methodologies with bioinformatics, creating a computational synergy capable of deciphering the intricate biological networks associated with ILDs. Network pharmacology has tailored the hypothesis from the conventional "one target, one drug" towards a "network target, multi-component therapeutics" approach. The fusion of traditional literature and computational technology can unveil novel drugs, targets, and pathways, augmenting effective therapies and diminishing adverse effects related to current medications. In conclusion, this review provides a comprehensive exposition of how Network Pharmacology tools can leverage the insights of Ayurveda and TCM to craft efficacious therapeutic solutions for ILDs. It sets the stage for future investigations in this captivating interdisciplinary domain, validating the use of traditional medicines worldwide.
本综述探讨了网络药理学的前沿领域及其革新间质性肺病（ILDs）治疗方法的潜力，ILDs是一个统称，包括间质性肺炎、尘肺病、结缔组织病相关的ILDs和结节病。该探索聚焦于传统医学的深厚遗产，尤其是阿育吠陀医学和中药，并着重于它们在ILD治疗中尚未得到充分探索的能力。这些古老的治疗体系以其整体方法和多方面的治疗方式为特点，为发现创新治疗策略提供了一个有前景的基础。此外，该综述强调了人工智能（AI）和机器学习（ML）方法与生物信息学的融合，创造了一种计算协同效应，能够解读与ILDs相关的复杂生物网络。网络药理学已将传统的“一个靶点，一种药物”假说转变为“网络靶点，多组分治疗”方法。传统文献与计算技术的融合能够揭示新的药物、靶点和途径，增强有效治疗效果并减少与现有药物相关的不良反应。总之，本综述全面阐述了网络药理学工具如何利用阿育吠陀医学和中药的见解，为ILDs制定有效的治疗方案。它为这个引人入胜的跨学科领域的未来研究奠定了基础，验证了传统医学在全球范围内的应用。
